FDA drug applications: Which is used to seek approval for a generic drug?

FDA drug applications: Which is used to seek approval for a generic drug?

• A. IND
• B. NDA
• C. ANDA
• D. BLA

Answer: (C)

The key idea is that generic drug approvals use an Abbreviated New Drug Application. Under the Hatch-Waxman framework, a generic manufacturer must show bioequivalence to a reference listed drug and ensure the same active ingredient, dosage form, strength, and route of administration. Rather than conducting full safety and efficacy trials, the generic can rely on the reference product’s data and must provide confirming bioequivalence data along with chemistry, manufacturing, and controls information and appropriate labeling. This pathway is specifically designed to approve copies of existing drugs more quickly and cost-effectively. In contrast, an Investigational New Drug application is used to begin clinical testing of a new substance, a New Drug Application is for marketing approval of a new molecular entity with full safety/efficacy data, and a Biologics License Application is for complex biological products rather than small-molecule generics.

The key idea is that generic drug approvals use an Abbreviated New Drug Application. Under the Hatch-Waxman framework, a generic manufacturer must show bioequivalence to a reference listed drug and ensure the same active ingredient, dosage form, strength, and route of administration. Rather than conducting full safety and efficacy trials, the generic can rely on the reference product’s data and must provide confirming bioequivalence data along with chemistry, manufacturing, and controls information and appropriate labeling. This pathway is specifically designed to approve copies of existing drugs more quickly and cost-effectively.

In contrast, an Investigational New Drug application is used to begin clinical testing of a new substance, a New Drug Application is for marketing approval of a new molecular entity with full safety/efficacy data, and a Biologics License Application is for complex biological products rather than small-molecule generics.